46 results about "Prostate cells" patented technology

A method for selecting a compound or a composition of matter for treatment of hyperproliferative disorders of the prostate in a mammal by administering the compound or the composition to a mammal (in vivo) or to a prostate cell culture (in vitro) and assessing the effect of the compound or the composition on the content of the transcription and / or translation product of a gene under the influence of at least one regulatory region of Vitamin D upregulated protein 1 (VDUP-1) gene and optionally assessing the effect of the compound or the composition on the content of apoptosis signalling kinase (ASK-1) and / or thioredoxin, in the prostate cells of said mammal or in the cells of the prostate cell culture. A substance for use in the treatment of hyperproliferative disorders of the prostate selected by the above method, a pharmaceutical composition comprising said substance, a method of treatment by of a hyperproliferative disorder of the prostate. A gene encoding VDUP-1 or a functional equivalent thereof for use as a medicament and a vector capable of expressing VDUP-1. A method of diagnosis of a hyperproliferative disorder of the prostate in a mammal by assessing the content of the transcription and / or translation products of at least one of the genes encoding ezrin, thioredoxin, peroxiredoxin 5, cyclin-dependent kinase 4, growth response protein CL6, defender against cell death 1, CD24, osteoactivin, vitamin D-upregulated protein 1, placental growth factor gene 1+2, Gata-4, duffy blood antigen, interferon-inducible 17-kDa membrane protein, 14-3-3 protein, CD9 antigen (p24), Ste-20 related kinase, ephrin type A receptor 5 precursor, programmed cell death factor 4 and DNA-methyltransferase 3a, in cells obtained from the prostate of said mammal. A kit for use in a method of diagnosis of a hyperproliferative disorder of the prostate in a mammal.

The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.

A method of detecting presence or absence of prostate cancer in a subject, both in vivo and ex vivo is disclosed. The method comprises analyzing mitochondria or a mitochondrial component in at least one prostate cell of the subject, whereby mitochondria an alteration in quantity and or characteristic is indicative of the presence or absence of the prostate cancer in the subject.

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (serpentine transmembrane antigens of the prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

The present invention provides a method of treating BPH using modified pore-forming proteins (MPPs). These MPPs are derived from naturally occurring cytotoxic proteins (nPPs) that kill cells by forming pores or channels in the cell membrane, resulting in cell death. The MPPs are generated by modification of the nPPs such that they are capable of being selectively activated at normal prostate cells. Such modification may include the addition of a prostate-specific protease cleavage site to the activation sequence, and / or the addition of a prostate-specific targeting domain to allow selective targeting of prostate cells. These MPPs are capable of selectively targeting and killing normal prostate cells in vivo. The MPPs may be used either alone or in combination with other therapies for the treatment of BPH.

Disclosed are methods for probing the immunogenic sugar moieties of prostate cancer cells. The methods detect a number of glyco-epitopes that are highly and differentially expressed among prostate cancers of various Gleason grades. The glyco-epitopes exist on the surfaces of prostate cells. The methods also comprise the detection of autoantibodies in prostate cancer subjects. The antibodies bound to a glyco-motif of N-glycans that is normally “cryptic.” This target is highly expressed in prostate cancers. Lectins and antibodies that detect these glyco-epitopes that expressed in prostate cancer tissues include Euonymus europaeus lectin (EEL); Psophocarpus Tetragonolobus Lectin-I (PTL-I); Griffonia Simplicifolia Lectin-I-A4 (GSL-I-A4); Griffonia Simplicifolia Lectin-I-B4 (GSL-I-B4); Sambucus nigra I agglutinin (SNA-I; Phaseolus vulgaris-L (PHA-L; Galanthus nivalis agglutinin (GNA); Narcissus pseudonarcissus agglutinin (NPA); Artocarpus integrifolia agglutinin (Jacalin); and mAb TM10 (IgM).

The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic prostate cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating prostate cancer and non-cancerous disease states in prostate tissue, identifying prostate tissue, monitoring and identifying and / or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered prostate tissue for treatment and research.

The present invention relates to organoids derived from a single cell, such as a prostate cancer cell, and methods and compositions relating to the production and use thereof, including cell culture medium for producing organoids and methods of personalized treatment for prostate cancer. The invention further provides a humanized mouse comprising a prostate organoid derived from a patient's prostate cell.

The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic prostate cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating prostate cancer and non-cancerous disease states in prostate tissue, identifying prostate tissue, monitoring and identifying and / or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered prostate tissue for treatment and research.

The invention provides a transgenic mouse and cell lines with a homozygous disruption of a chromosomal PTEN gene in prostate cells. The mouse progresses from hyperplasia to metastatic cancer and can be used to identify prostate cancer therapeutics and genes that are differentially regulated during androgen dependent and androgen independent prostate cancer progression.

The invention provides methods, nucleic acids and kits for detecting prostate cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.

The invention provides methods, nucleic acids and kits for detecting prostate cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.

The present invention relates to a composition for the detection and the treatment of prostate cells and to methods for the diagnostic and therapeutic treatment of a human being using the composition according to the invention.

A polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Splice Variant-Novel Gene Expressed in Prostate (SV-NGEP). Polynucleotides encoding SV-NGEP are also disclosed, as are vectors including these poynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies and immunoconjugages are disclosed that specifically bind SV-NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds SV-NGEP, or a polynucleotide encoding SV-NGEP. Assays are disclosed for the detection of prostate cancer. Pharmaceutical compositions including an SV-NGEP polypeptide, an antibody that specifically binds SV-NEGP, or a polynucleotide encoding SV-NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.

A nutrition wine used for restoring gene and activating prostate cell comprises the following parts: honeysuckle flower, dandelion, purslane, cactus and barbat skullcap 25-35 parts equally, banksia rose, sword bean and cyperus tuber 25-35 parts equally, frank incense, chuanxiong rhizome, spatholobus stem, safflower and achyranthes 25-35 parts equally, cornaceae, chebula fruit, Chinese gall, lotus seed and schisandra fruit 25-35 parts equally, bee honey 4-6 parts, ganoderam lucidum karst bacterial and marasin as edible bacterial 4-6 parts equally, yeast1-2 parts, brewers' yeast 1-2 parts, 75-85 degree edible white wine is 2 times as much as the fermentation material (the fermentation material is made by the fermentation of the above material). The preparing method produces the functional nutrient food utilizing microbiological fermentation, which activates the prostate cell, restores varied cell and achieves rehabilitation of prostate.

The present invention provides a method for treatment of prostatic hyperplasia with banana flower extract. Such banana flower extract can suppress the proliferation of prostate cells and their ability to synthesize dihydrotestosterone. In another aspect, the banana flower extract is also used for ameliorating urinary disturbance. The banana flower extract is a water-soluble extract obtained by sonication and can further be utilized to provide alternatives or supplements for ameliorating symptoms associated with prostatic hyperplasia.

The present invention relates to compositions and methods for enhancing the oncolytic activity of replication-competent, target cell-specific adenovirus vectors by modification of the E1A gene product. The target cell-specific replication-competent adenovirus vectors comprise a chimera of an adenovirus gene essential for replication, preferably an early gene, and the Androgen receptor (or a portion thereof) under the transcriptional control of a cell type-specific transcriptional regulatory element (TRE). By providing for cell type-specific transcription through the use of one or more cell type-specific TREs, the adenovirus vectors effect prostate-specific cytotoxicity due to selective replication.

Immortalized human cell lines derived from prostate cells are disclosed. Immortalized cells derived from a human epithelial prostate tissue cancer tumor are provided, as well as immortalized cells derived from healthy human epithelial prostate tissue from the same patient. Methods for utilizing such immortalized cell lines for researching, screening, and evaluating antimalignancy therapies and drug candidates are also disclosed.

The invention discloses a novel application of an alchornea trewioides extract in the pharmacy field, and in particular, an application of an alchornea trewioides extract in preparing drugs for treating nonbacterial prostatitis; and an application of an alchornea trewioides extract in preparing drugs for treating nonbacterial prostatic hyperplasia; In addition, the invention also discloses a drug composition for treating nonbacterial prostatitis and prostatic hyperplasia with the alchornea trewioides extract as an active component. Through experiment, the applicant finds that the alchornea trewioides extract can significantly decrease the prostate wet weight and the prostate index of a model animal, has a good inhibition effect on prostate glandular swelling of a nonbacterial prostatitis model rat, can improve blood circulation and promote the softening of the prostate glandular texture, and can mitigate interstitial hyperemia, edema, inflammatory cell infiltration and cell degeneration of prostate cells. Compared with existing and common western medicine, the alchornea trewioides extract has comparable or even better efficacy and less toxicity, and is safer for medication.

A novel prostate cancer marker is described that is found in cancerous and normal prostate cells of individuals that have prostate cancer but is not found in the prostate of individuals without prostate cancer. The marker also is present in normal tissue adjacent to tumor tissue in individuals having prostate cancer. The marker, however, is absent in the prostate of individuals without prostate cancer. Methods employing the novel prostate cancer marker of the invention to predict the occurrence of the prostate disease, monitor the progression of prostate cancer and effect the treatment of prostate cancer, also are described.